PROSPECTIVE EVALUATION OF SERUM MALDI TOF MS PROTEOMIC PROFILE PREDICTIVE OF OUTCOME IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH STANDARD TREATMENT STRATIFIED ACCORDING TO MGMT - ND

FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点开始时间: 2009年10月2日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•-C.I. firmato orima di sottoporsi a qualsiasi procedura;eta` compresa tra i 18 e i 70 anni; nuova diagnosi istologica di GBM; etc.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patient who can not comply with planned protocols procedures
•Prior chemotherapy within the last 5 years
•Prior RT of the head
•Receiving concurrent investigational agents or has received an investigational agent
•Prior anti-angiogenic therapy
•Placement of Gliadel? wafer at surgery
•Planned surgery for other diseases
•History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for more than 5 years are eligible for this study
•Any uncontrolled intercurrent illness (e.g. high blood pressure, unstable angina, serious cardiac arrhythmia, diabetes ), also including severe infection, which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety
•Subject is pregnant (positive pregnancy test [serum -HCG] at screening), or is currently breast-feeding
•Any psychological, familiar, sociological, legal or geographical state that could potentially interfere with the study protocol compliance; these conditions should be evaluated before patients enrolment

发起方

FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR